New York, US – August 26, 2019 – Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) cell therapy are two most popular immune therapies that accelerate the drug discovery and development process for the treatment of various diseases, especially cancers, which utilize immune cells in human body to identify, locate and finally kill tumor cells, achieving the transformation from basic immune research to clinical trials. The CAR Hybrid TCR-T (CHyT-T) cell therapy development platform in Creative Biolabs integrates the unique advantages of TCR-T and CAR-T cell therapy, and overcomes their limitations, eventually powering T cells for cancer cures.
“As a novel engineered T cell therapy developed by our seasoned scientists, the CHyT is capable of participating in the whole TCR process to fully activate T cells by conjugating the specific tumor antigen to the TCR complex via high-affinity scFv which can recognize the antigens on tumor cells without HLA dependence, thereby fully activating T cells and completing a powerful and consistent tumor attack.” – Introduced by the senior scientist of Creative Biolabs.
“According to the properties of our clients’ project, our technicians will propose the most appropriate solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence by unrivaled, proprietary drug design, study data, product candidate, advanced project lifecycle management, as well as real-time data.”
The end-to-end solutions to CAR Hybrid TCR-T Cell Therapy include:
- Biomarker Identification and Selection: De novo discovery of potential cancer biomarkers and selection of the most suitable T cell therapy targets;
- scFv Generation: In-house inescapable antibody sequence data base and ScFv affinity measurement and optimization;
- CHyT Design and Construction: Customized lentiviral or retroviral CHyT construction;
- Virus Packaging & CHyT Gene Delivery: High titer transduction-ready pseudoviral particles;
- CHyT -T In Vitro Validation Assays: Characterization and cytokine release and cytotoxicity assay;
- CHyT-T Preclinical In Vivo Assays: Efficacy test, viability and bio-distribution study, toxicity evaluation.
Through the comprehensive CHyT-T development process covering early discovery, nonclinical and commercialization services, Creative Biolabs can offer an advanced T cell therapy without conventional limitations of CAR-T and TCR-T Cell Therapy. More information can be reached at https://www.creative-biolabs.com/car-t/.
About Creative Biolabs
As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, the established leading experts in TCR and CAR T&NK cell immune therapy development offer the one-stop custom services that cover the entire new drug development pipeline, and an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, a unique unparalleled CAR construction and production platform has been built up for all four CAR generations.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States